



PHARMACEUTICAL 2021









PHARMACEUTICAL 2021



Nurix Therapeutics Inc. Rank 83 of 409



The relative strengths and weaknesses of Nurix Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nurix Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Nurix Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 57%, being 412% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	298,434
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	44,539
Liabilities, Non-Current	61,535
Other Assets	91,237
Other Compr. Net Income	89
Other Expenses	-20,535
Other Liabilities	0
Other Net Income	0
Property and Equipment	6,672
Research and Development	66,494
Revenues	19,026
Selling, General and Administrative Expense	16,309

Output Variable	Value in 1000 USD
Assets	396,343
Liabilities	106,074
Expenses	62,268
Stockholders Equity	290,269
Net Income	-43,242
Comprehensive Net Income	-43,198
Economic Capital Ratio	57%